This site is intended for healthcare professionals only
Share this article

Consultation on draft SIGN guideline on type 2 diabetes

The Scottish Intercollegiate Guidelines Network (SIGN) has published a draft update to its guidance on the pharmacological management of type 2 diabetes, and is inviting healthcare professionals to comment on the proposal.

The draft focuses on the optimal glycaemic targets for the prevention of micro- and macrovascular complications (unchanged from the previous SIGN 116 guidance) and the risks and benefits of glucose-lowering drugs and insulins. An updated treatment algorithm is also due to be published but is not yet available in the draft version.

SIGN is interested in the views of healthcare professionals regarding the comprehensiveness and accuracy of interpretation of the evidence base behind the guideline. Interested parties can access the draft at:

Feedback should be submitted before 12 pm on 26 May 2017.

Related content
Prevention of diabetic maculopathy: Trial of oral medication begins
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals


By clicking ‘Subscribe’, you are agreeing that are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.